Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines

Luis G Bermúdez-Humarán, Pascale Kharrat, Jean-Marc Chatel, Philippe Langella*

From 10th Symposium on Lactic Acid Bacterium
Egmond aan Zee, the Netherlands. 28 August - 1 September 2011

Abstract

Food-grade Lactic Acid Bacteria (LAB) have been safely consumed for centuries by humans in fermented foods. Thus, they are good candidates to develop novel oral vectors, constituting attractive alternatives to attenuated pathogens, for mucosal delivery strategies. Herein, this review summarizes our research, up until now, on the use of LAB as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Most of our work has been based on the model LAB Lactococcus lactis, for which we have developed efficient genetic tools, including expression signals and host strains, for the heterologous expression of therapeutic proteins such as antigens, cytokines and enzymes. Resulting recombinant lactococci strains have been tested successfully for their prophylactic and therapeutic effects in different animal models: i) against human papillomavirus type 16 (HPV-16)-induced tumors in mice, ii) to partially prevent a bovine β-lactoglobulin (BLG)-allergic reaction in mice and iii) to regulate body weight and food consumption in obese mice. Strikingly, all of these tools have been successfully transposed to the Lactobacillus genus, in recent years, within our laboratory. Notably, anti-oxidative Lactobacillus casei strains were constructed and tested in two chemically-induced colitis models. In parallel, we also developed a strategy based on the use of L. lactis to deliver DNA at the mucosal level, and were able to show that L. lactis is able to modulate the host response through DNA delivery. Today, we consider that all of our consistent data, together with those obtained by other groups, demonstrate and reinforce the interest of using LAB, particularly lactococci and lactobacilli strains, to develop novel therapeutic protein mucosal delivery vectors which should be tested now in human clinical trials.

Introduction

The administration of therapeutic molecules via mucosal routes offers several important advantages over systemic delivery such as reduction of secondary effects, easy administration and the possibility to modulate both systemic and mucosal immune responses [1]. Moreover, direct delivery of the appropriate medical molecules to exert their effects at mucosal surfaces is a very efficient prophylactic and therapeutic strategy. Mucosal surfaces are the primary interaction sites between an organism and its environment and they thus represent the major portal of entry for pathogens. In the last fifteen years, there have been several reports of successful immunisation with a variety of mucosal vector vaccines [2]. They can induce efficient systemic immune responses with less collateral side effects than systemic vaccines [1]. Additionally, mucosal immunisation is more easily performed, without the need for needles and syringes, thereby eliminating the requirement for trained personnel (important feature for mass vaccination programs) [3]. Nevertheless, a major disadvantage is that a large amount of protein needs to be administered, due to the fact that the majority of protein will degrade, with very small quantities surviving degradation at mucosal surfaces such as the gastrointestinal tract [1]. Therefore, the development of new vectors, able to

* Correspondence: philippe.langella@jouy.inra.fr
INRA, UMR1319 Micalis, Commensal and Probiotics-Host Interactions Laboratory, Domaine de Vilvert, 78352 Jouy-en-Josas Cedex, France
Full list of author information is available at the end of the article

© 2011 Bermúdez-Humarán et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
efficiently deliver molecules to target tissues represents a technological challenge.

Today, sufficient data is available supporting the fact that lactic acid bacteria (LAB), notably lactococci and lactobacilli, are excellent candidates as delivery vectors of therapeutic proteins, in the development of novel preventive and therapeutic strategies for humans. LAB are non-pathogenic Gram-positive bacteria and they have an extraordinary safety profile, since they have been widely consumed for centuries by humans in fermented foods. Therefore, they constitute an attractive alternative to attenuated pathogens, which are the most popular live vectors being used currently. Attenuated pathogenic bacteria, such as derivatives of Mycobacterium, Salmonella, and Bordetella spp. are particularly well adapted to interact with mucosal surfaces as most of them they normally use to initiate the infection process. Unfortunately, these bacteria can recover their pathogenic potential and are therefore not entirely safe for use in humans, especially in children and immunosuppressed patients. Several detailed reviews of vector delivery strategies, based on LAB, have been published within the last five years, of which three are particularly exhaustive and convincing [4-6]. Herein, we will be summarizing our current research and advances on the use of lactococci and lactobacilli as live delivery vectors of proteins with health interest. We will also be describing the use of LAB as DNA-vaccine-delivery vehicles to deliver DNA directly to antigen-presenting cells of the immune system.

1. Lactic acid bacteria as mucosal delivery vectors of antigens and cytokines

The immunogenicity of soluble proteins administered orally or intranasally is generally low and can be significantly enhanced by either coupling the protein to a bacterial carrier or by genetic engineering of bacteria resulting in the production of the desired antigen. As previously mentioned, food-grade or commensal Gram-positive bacteria constitute an attractive alternative to attenuated pathogenic bacteria [6]. In particular, the model LAB Lactococcus lactis and certain species of lactobacilli possess a number of properties, making them attractive candidates for the development of mucosal vaccines [7]. Moreover, many antigens and/or cytokines have been successfully expressed in LAB, and mucosal administration of these genetically engineered LAB has been shown to elicit both systemic and mucosal immunity (see additional file 1).

The production of a desired antigen by LAB can occur in three different cellular locations: i) intracellular, which allows the protein to escape harsh external environmental conditions (such as gastric juices in the stomach after oral administration of the recombinant strain) but requires cellular lysis for protein release and delivery, ii) extracellular, which allows the release of the protein into the external medium, resulting in direct interaction with the environment (food product or the digestive tract), and iii) cell wall-anchored, which combines the advantages of the other two locations (i.e., interaction between the cell wall-anchored protein and the environment, in addition to protection from proteolytic degradation). In this context, several studies have compared the production of different antigens in LAB, using all three locations and evaluated the subsequent immunological impact [Reviewed in Refs. [6] and [7]]. Even if the comparison between the localization is difficult due to the amount of protein depending on the localization, these studies demonstrated that the highest immune response was usually obtained with cell-wall anchored antigens exposed to the surface of LAB. Therefore, most of the recent LAB vaccination studies have selected surface exposure of the antigen of interest, rather than intra- or extracellular production.

**Lactococcus lactis as live delivery vector of proteins of health interest**

*L. lactis* is the most widely used LAB in the production of fermented milk products, and is considered as the model LAB because many genetic tools have been developed in particular for heterologous protein production [8]. Moreover, *L. lactis* is considered to be a good candidate for heterologous protein production because it secretes relatively few proteins and only one, Usp45, in detectable quantities [9,10]. In addition, the most commonly used laboratory *L. lactis* strain (MG1363) is plasmid-free and does not produce any extracellular proteases [11]. However, the major advantage of using *L. lactis* as a live vector for mucosal delivery of therapeutic proteins resides in its extraordinary safety profile, since this bacterium is catalogued as a non-invasive and non-pathogenic organism with a GRAS status. Finally, the capacity of *L. lactis* to produce many different proteins of health interest has been clearly demonstrated in the last two decades (see additional file 1). All of these features explain why most of the relevant studies focusing on the use of LAB as protein and DNA delivery vectors have been performed with *L. lactis*.

**Heterologous proteins production in L. lactis**

Currently, several inducible and constitutive expression signals are available for *L. lactis*[2][3,6]. In our studies, we mainly used the nisin inducible promoter (PnisA), which is the major element of the NICE (Nisin Induced Controlled Expression) system [12]. Nisin is a bacteriocin produced by *L. lactis*, which contains eleven amino acids (nisABTICIPRFEG) encoding for biosynthesis and immunity against nisin [13]. The nisA gene encodes for the structural nisin gene, whereas nisRK encode for the dual-component system responsible for
the induction of other genes within the cluster. All of our genes of interest were cloned downstream of P\textsubscript{nua} and the resulting plasmid was introduced in \textit{L. lactis} NZ9000 (MG1363 strain carrying nisRK genes on its chromosome). Addition of sub-inhibitor nisin concentration levels, into the culture medium, induces the expression of the gene of interest proportionally to the dose of nisin used. This system is now considered as the most efficient one for heterologous expression in \textit{L. lactis}[14]. We have thus developed an efficient heterologous protein production-secretion system in \textit{L. lactis} based on \textit{P}_{nisA} and a small stable and well-characterized protein, \textit{Staphylococcus aureus} nuclease (Nuc) [15].

A family of three expression vectors: pCYT, pSEC, and pCWA was developed, to allow protein targeting to be either intracellular, secreted, or cell wall anchored, respectively. We also constructed a fourth expression vector called pSEC:LEISS, which contains a synthetic propeptide (LEISSSTCDA) identified as a production-secretion booster [16]. These vectors, also functional in several other LAB species including lactobacilli, streptococci, enterococci and bifidobacteria, have been successfully used to produce approximately 50 different heterologous proteins in \textit{L. lactis} up to date (see additional file 1). More recently, we also developed a new bile salts-inducible promoter, which is currently being tested in \textit{in vivo} experiments (data not shown). Concerning the possible host factors affecting production-secretion in \textit{L. lactis}, we have identified \textit{ybdD} which, once inactivated, induces an overproduction of secreted protein [Morello \textit{et al}., unpublished data]. In addition, the secretion machinery for \textit{L. lactis} has also been complemented with \textit{B. subtilis} SecDF, which induced an increase in both production and secretion rates [17]. Within our panel of \textit{L. lactis} strains, we also have three mutants: one inactivated in the unique extracellular housekeeping protease HtrA [18], one inactivated in the major intracellular protease ClpP, and one inactivated in both HtrA and Clp [19]. These strains are essential to reach controlled and stable production of highly degraded proteins in the wild type \textit{L. lactis} strain [20].

2. Use of recombinant lactococci to induce mucosal and systemic immune responses against bacterial and viral pathogens

Currently, a number of studies support the use of recombinant \textit{L. lactis} to induce mucosal and systemic immune responses against a desired antigen [2,7]. In 1990, the first attempt to use \textit{L. lactis} as a mucosal vaccine was performed with killed recombinant lactococci producing a cell wall-attached form of a \textit{Streptococcus mutans} protective antigen (PAC). Mice immunized orally with this killed \textit{L. lactis} recombinant strain developed PAC-specific serum IgG and mucosal IgA antibodies [21]. These results demonstrated, for the first time, that \textit{L. lactis} can efficiently present an antigen to the immune system. In 1993, Wells \textit{et al.} [22] then reported, for the first time, of the use of live recombinant \textit{L. lactis}, producing tetanus fragment C (TTFC), to protect mice via subcutaneous injection against a lethal challenge with tetanus toxoid. Afterwards, the same group evaluated the effect of immunization route (oral or nasal administration) on live recombinant lactococci producing TTFC in mice [23,24]. Oral immunization in mice resulted in a lower serum IgG and mucosal IgA antibody response as compared to nasal immunisation; whereas the protective efficacy (\textit{i.e.} challenge with tetanus toxin) was similar between both routes. Many studies have been conducted to analyze the expression of viral, bacterial or eukaryotic heterologous proteins in \textit{L. lactis} (see additional file 1).

The immunogenicity of the resulting recombinant strains has been evaluated, in mouse models in some cases, with very promising results. Amongst them, one of the best documented projects is based on the use of recombinant \textit{L. lactis} producing human papillomavirus type 16 (HPV-16) E7 antigen. This viral protein is considered as a major candidate antigen for vaccines against HPV-related cervical cancer, the second cause of cancer death in women. The intracellular production of E7 antigen led to its rapid degradation in the cytoplasm of \textit{L. lactis}, even when produced in a protease-free \textit{clpP} strain [25]. In contrast, secreted and cell wall-anchored forms are rescued from proteolysis and produced a higher level of E7 in \textit{L. lactis}[25,26]. Antigen-specific humoral (production of E7 antibodies) and cellular (secretion of IL-2 and IFN-\textgamma; cytokines) responses were observed after intranasal administration of recombinant lactococci expressing E7 antigen at different levels and in cellular locations to mice. The responses were significantly higher in mice immunized with \textit{L. lactis} expressing E7 as a cell wall-anchored form [27]. Subsequently, the protective effect of mucosally co-administered live \textit{L. lactis} strains expressing cell wall-anchored E7 and a secreted form of interleukin-12 to treat HPV-16-induced tumors in a murine model was then evaluated [28]. When challenged with lethal levels of tumor cell line TC-1 expressing E7, 50% of pre-treated mice demonstrated complete prevention of TC-1-induced tumors. Therapeutic immunization with these recombinant strains, (i.e., 7 days after TC-1 injection) induced regression of palpable tumors in 35% of treated mice. These preclinical results suggest the feasibility of mucosal vaccination and/or immunotherapy against HPV-related cervical cancer using genetically engineered lactococci. Although most immunological studies have been performed with \textit{L. lactis} producing TTFC and E7 antigen, the reports supporting the use of recombinant lactococci as mucosal vaccines continue to grow, and approximately more than 50 peer-reviewed publications have validated this potential to date (see additional file 1).
Use of recombinant lactococci in cow’s milk allergy model

Cow’s milk allergy (CMA) is a complex disorder and is the most common allergy in young infants, with an incidence rate of 2-6%, decreasing to 0.1-0.5% in adulthood. CMA develops early in infancy within 12 to 24 months of birth, but 80-90% of affected children recover by acquiring tolerance to cow’s milk by the age of 5 years [29,30]. L. lactis has been engineered to produce β-lactoglobulin (BLG), one of the major allergens found in cow’s milk, resulting in LL-BLG. The recombinant BLG was produced predominantly in a soluble, intracellular, and mostly denatured form. Mucosal administration of LL-BLG strain induced BLG specific fecal IgA, although allergen-specific IgE, IgA, IgG1 or IgG2a were not detected in mice sera [31]. A similar immune response was reported after oral administration of recombinant L. lactis secreting a T-cell determinant IgE epitope of BLG [32]. Adel-Patient et al [33] then demonstrated that oral administration of recombinant L. lactis strains producing different amounts of recombinant BLG partially prevents mice from sensitization.

Oral pre-treatment with these strains prevented a Th2-type immune response elicited by systemic sensitization, via reduction of specific IgE and the induction of allergen-specific IgG2a and fecal IgA antibodies. The intensity of the Th1 immune response induced correlates with the amount of recombinant BLG produced, since the most effective strains were those producing the highest amount of BLG [33].

Similar to oral administration, intranasal delivery of recombinant L. lactis strains did not induce the secretion of BLG specific antibodies, but elicited IFN-γ production in murine splenocytes after BLG re-stimulation. Intranasal pre-treatment of mice with LL-BLG reduced airway eosinophilia influx and IL-5 secretion in broncoalveolar lavage (BAL) after intranasal allergen challenge. In the same study, intranasal co-administration of recombinant LL-BLG and LL-IL12 elicited a protective Th1 immune-response, inhibiting the allergic response in mice without affecting specific BLG IgE secretion [34]. Elsewhere, we also showed that intranasal administration of LL-IL12 strain decreased allergy symptoms in an asthma model induced by ovalbumin [35]. The effects of intranasal administration of LL-BLG strain were also tested in a therapeutic protocol. In orally sensitized mice, intranasal administration of recombinant strain reduced IgG1 production but did not influence specific BLG IgE or IgG2a secretion. After intranasal challenge, a mild decrease in IL-4 and IL-5 secreted into BAL was detected [36].

Effects of intranasal administration of recombinant L. lactis strains secreting human leptin in ob/ob mice

Leptin is a 16 kDa protein encoded by the obese (ob) gene, and is an adipocyte-derived pleiotropic hormone that modulates a large number of physiological functions, including control of body weight and regulation of the immune system [37]. In humans, leptin plays a crucial role in regulation of body weight, as demonstrated by morbid obesity in patients with congenital mutations in either leptin or the leptin receptor gene [38-41]. When body fat increases, leptin inhibits food intake and stimulates energy expenditure to control body weight. Although leptin treatment induced remarkable weight-loss in patients with rare congenital leptin deficiency [42-45], it showed poor efficiency in most obese patients. Indeed, clinical trials involving subcutaneous administration of recombinant leptin to obese subjects indicated that a significant reduction of body weight was only observed if serum leptin concentrations were 20- to 30-fold higher than normal physiological levels [46]. This poor response was attributed in part to insufficient transport of leptin across the blood brain barrier in obese patients [47].

Since intranasal delivery is an efficient route for administration of drugs directly to the brain [48-50], we considered that intranasal leptin administration may be an interesting strategy to bypass the blood brain barrier in leptin resistant humans. Thus, the aim of our project was to measure the effect of intranasal administration of a recombinant L. lactis strain secreting a biologically active form of leptin (LL-LEP) in ob/ob mice. We first demonstrated that the secreted recombinant leptin is a fully biologically active hormone, by showing its capacity to stimulate a STAT3 reporter gene in HEK293 cells transfected with the Ob-Rb receptor gene [51]. The immuno-modulatory activity of the LL-LEP strain was then evaluated in vivo by co-expression with the L. lactis strain expressing human papillomavirus type-16 (HPV-16) E7 protein (LL-LEP) [51]. In C57BL/6 mice immunized intranasally with LL-LEP and LL-E7 strains, the adaptive immune response was significantly higher than in mice immunized with LL-E7 only, demonstrating the adjuvanticity of leptin. We then analyzed the effect of daily intranasal administration of LL-LEP in ob/ob mice and thus observed that this treatment induced a significant reduction in body weight gain and food intake [51]. These results demonstrate that leptin can be produced and secreted in an active form by L. lactis, and that the LL-LEP strain regulated in vivo antigen-specific immune responses, as well as body weight and food consumption.

Immune response to antigens delivered by Lactobacillus spp

The use of genetically modified lactobacilli (i.e. Lb. fermentum, Lb. acidophilus, Lb. casei and Lb. plantarum) to produce heterologous proteins and to develop a new generation of mucosal vaccines was first proposed during the 90s decade [52,53]. By the end of the 90s and into the early 2000s, several laboratories had successfully utilized
recombinant strains of Lb. casei and Lb. plantarum as vehicles for delivery of medically relevant proteins to mucosal surfaces, with both strains stimulating strong local immune responses [6,54]. Approximately 50 peer-reviewed publications have already been published confirming the advantages of the Lactobacillus genus to serve as live mucosal vaccines, since lactobacilli can persist longer in the digestive tract and some strains have probiotic properties (i.e. show health-promoting activities for humans and animals) [54]. Similar to L. lactis, several studies analyzing the expression of a variety of viral, bacterial or eukaryotic origin proteins in Lb. plantarum and Lb. casei have been conducted (see additional file 1). We have evaluated the immunogenicity of E7 antigen producing recombinant Lb. plantarum in mouse models with promising results [55].

**Use of recombinant Lb. casei in cow’s milk allergy model**

We recently developed a recombinant strain of Lactobacillus casei capable of producing BLG. The immunomodulatory potency of intranasal and oral administration of this recombinant lactobacilli on a subsequent sensitization of mice to BLG was investigated by Hazebrouck et al. [56], who analyzed the influence of the administration route on the immune response elicited by the recombinant BLG Lb. casei producing strain. Intranasal pre-administration of the BLG-producing Lb. casei enhanced BLG-specific IgG2a and IgG1 responses, but did not influence BLG-specific IgE production in sensitized mice. Unexpectedly, oral pre-administration led to a significant inhibition of BLG-specific IgE production, whereas IgG1 and IgG2a responses were not stimulated in sensitized mice. The production of IL-17 by BLG-reactivated splenocytes was similar between oral and intranasal route administrations. However in BLG-reactivated splenocytes from mice intranasally pretreated, a greater secretion level of Th1 cytokines (IFN-γ and IL-12) and Th2 cytokines (IL-4 and IL-5) was detected, suggesting a mixed Th1/Th2 cell response; whereas only production of Th1 cytokines, but not Th2 cytokines, was enhanced in BLG-reactivated splenocytes from mice orally pretreated. Those results indicate that the mode of administration of recombinant LAB may be critical for their immunomodulatory properties [56].

**Anti-oxidative proteins delivery by Lb. casei in colitis-induced murine models**

Inflammatory bowel diseases (IBD) constitute a group of disorders characterized by chronic and relapsing inflammation of the gastrointestinal tract (GIT). The two most common forms of IBD are Crohn’s disease and ulcerative colitis, which are associated with an influx of neutrophils and macrophages, resulting in the consequent production of inflammatory mediators such as proteases, cytokines and reactive oxygen species (ROS) [57]. ROS include the superoxide radical (O2•−), hydrogen peroxide (H2O2), and the hydroxyl radical (HO•) [58], which have all been demonstrated to be both cytotoxic and mutagenic (i.e. cause damage to cellular lipids, proteins and DNA) [59]. To detoxify ROS, cells have evolved protective mechanisms via antioxidant enzymes such as superoxide dismutases (SOD) and catalases (CAT), which degrade O2•− and H2O2, respectively, thereby preventing the formation of HO• [60]. Thus, therapeutic use of antioxidant enzymes to decrease ROS amount level is a promising strategy to prevent and/or cure IBD. Several studies have shown that LAB, such as lactobacilli, may play a preventative role in IBD [61,62]. Under this context, we originally demonstrated that Lb. casei BL23 strain can attenuate moderate Dextran Sodium Sulfate (DSS) induced colitis in mice [63]. However, the use of a recombinant Lb. casei BL23 strain producing manganese CAT (MnCAT) did not improve the protective effect of inflammation reduction [63]. On the other hand, other recent studies have successfully reported the use of either recombinant Lb. gasseri or Lb. plantarum strains to produce and deliver in situ biologically active manganese SOD (MnSOD) to treat colitis in an interleukin-10 (IL-10) knockout mouse model and in a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats [64][65]. We then cloned MnSOD from Lactococcus lactis into Lb. casei BL23 to evaluate the potential increase in the aforementioned protective effect towards ROS by delivery of MnSOD [66]. We therefore compared the effect of intragastric administration of Lb. casei BL23 MnSOD alone or in combination with Lb. casei BL23 MnCAT in the murine model of DSS 3%-induced colitis. Based on histological scores, a significant reduction of caecal and colonic inflammation was observed with either administration of Lb. casei BL23 MnSOD alone or the co-administration of Lb. casei BL23 MnCAT and Lb. casei BL23 MnSOD. However, there was no additional improvement in inflammation reduction with the administration of Lb. casei BL23 MnCAT as compared to administering Lb. casei BL23 MnSOD alone. These results suggest that Lb. casei BL23 MnSOD may have an anti-inflammatory effect on gut inflammation. More recently, we demonstrated that both Lb. casei BL23 MnSOD and MnCAT were able to significantly attenuate TNBS-induced inflammation damage in mice as shown by higher survival rates, decreased animal weight loss, lower bacterial translocation to the liver and the prevention of damage to the large intestine [66].

**3. Recombinant lactic acid bacteria as DNA delivery vehicles**

The advantage of DNA vaccines relies in their ability to induce both cellular and humoral Th1 immune responses [67,68]. In contrast to bacteria-mediated delivery of protein antigens, bacteria-mediated delivery of DNA vaccines leads to the expression of post-translationally modified antigens by host cells resulting in presentation of conformationally restricted epitopes to the immune system [69].
As for protein delivery, the use of food-grade lactococci and lactobacilli as DNA delivery vehicles is a promising alternative to attenuated pathogens. **L. lactis is able to modulate the host immune response through cDNA delivery**

Recombinant BLG is expressed mainly in denatured form with *E. coli* or *L. lactis*, whereas its production, in eukaryotic cells, is in the native conformation [31,70]. *L. lactis* strains have been used to deliver an expression cassette encoding BLG cDNA, under the transcriptional control of the CMV viral promoter, into the Caco-2 epithelial cell line. The expression cassette was inserted into a *L. lactis* replicating plasmid. Production and secretion of BLG was observed in Caco-2 cells after incubation with *L. lactis* carrying the expression plasmid, demonstrating that non invasive *L. lactis* can deliver fully functional plasmids into epithelial cells. Interestingly, no production of BLG was observed when Caco-2 cells were co-incubated with purified plasmid alone or mixed with *L. lactis*, suggesting that the plasmid requires to be inside the bacterium in order to achieve transfer into epithelial cells with subsequent BLG production [71]. After oral administration of *L. lactis* in mice, carrying the eukaryotic expression cassette encoding for BLG, both BLG cDNA and protein were detected in the small intestine 72 hours after the final administration. No BLG (protein/dna or both) was detected 6 days after the last oral administration. Mice developed a BLG specific Th1 primary immune response, characterized by a weak and transitory IgG2a serum response. In sensitized pretreated mice, IgE and IL-5 concentrations decreased by 70 and 40%, respectively as compared to sensitized naive mice. Moreover, only splenocytes from pre-treated mice secreted IFN-γ after BLG specific re-activation [72]. The in situ production elicits a specific immune response protecting the mice from further sensitization with cow’s milk proteins. To our knowledge, this is the first evidence of functional genetic material transfer from food-grade transiting bacteria to a host.

**Recombinant invasive lactococci as DNA delivery vehicles**

As demonstrated with recombinant *E. coli*, invasion of the host cell is a limiting step to achieve efficient DNA vaccine delivery [73]. To increase lactococcal DNA vaccine delivery efficiency, *L. lactis* was rendered invasive by expression of the inlA gene of *Listeria monocytogenes*, encoding for the Internalin A surface protein, which mediates the invasion of non phagocytic cells by *L. monocytogenes*[74,75]. Once expressed by *L. lactis*, InlA can promote the internalization of lactococci into the human epithelial line Caco-2 in vitro and into enterocytes in vivo after oral administration to guinea pigs. In addition, *L. lactis* InlA+ can deliver a functional plasmid encoding for GFP, and about 1% of Caco-2 cells express GFP after co-culture with this strain [76]. Recombinant invasive *L. lactis* strains expressing the *Staphylococcus aureus* Fibronectin Binding Protein A encoding gene also showed a heightened ability to be internalized into mammalian cells as compared to the control strain. Consequently, both recombinant invasive strains were more efficient in eGFP expression plasmid delivery into Caco-2 cells, resulting in a higher number of GFP producing cells [77]. *In vivo*, *L. lactis* InlA+ was able to invade guinea pig enterocytes after oral administration [76].

**Conclusions and future challenges**

We consider that all of our consistent data, together with those obtained from other groups (see additional file 1), reinforce the interest in using lactococci and lactobacilli strains to develop novel therapeutic protein mucosal delivery vectors, which should be tested now in human clinical trials. Therefore, a biocontainment strategy to prevent the dissemination in the environment of these genetically modified LAB should be developed before they can be used in humans as it is mentioned in a recent review on these strategies [78]. Following the demonstration that an IL-10-producing *L. lactis* strain (LL-IL10) could treat colitis in mouse models [79], Steidler *et al* developed the first biocontainment system for LL-IL10 strain in order to be allowed to start the first human clinical study using this recombinant strain. To address these safety concerns with the use of LL-IL10 in humans, the chromosomal thymidine kinase (thuA) gene was replaced by the gene encoding for IL-10 to generate a thymidine auxotroph phenotype. In the absence of thymidine or thymine, the viability of the thuA LL-IL10 strain was reduced by several orders of magnitude and containment was validated *in vivo* in pigs [80]. A phase I clinical trial was then conducted with the thuA LL-IL10 strain in human patients suffering from Crohn’s disease, demonstrating that the containment strategy was effective [81]. Following those positive results, a phase IIa trial was performed and a press release was published by the end of 2009 revealing that all three primary endpoints of the study have been met: i) safety and tolerability; ii) environmental containment and iii) assessment of biomarkers associated with the strain. With respect to the secondary endpoint, the clinical results did not reveal a statistically significant difference in mucosal healing versus placebo. In view of these results, the authors of this pioneering human clinical trial and other teams involved in this promising field should now consider the optimization of some aspects of their LAB delivery strategy. The improvement should be done at different levels such as the nature i) of the delivered molecule; ii) of the LAB species as *Lb. casei* for example seems to show some advantages compared to *L. lactis* and iii) of the expression system to increase the quantitites of the delivered molecule *in situ*. Such efforts should and need to be continued because the future of prophylactic and therapeutic strategies based on recombinant lactococci and
lactobacilli requires clear demonstration of their efficacy in such human clinical trials, which will lead to their better acceptance.

Additional material

Additional file 1: Summary of therapeutic proteins expressed by lactococci and lactobacilli and validated in animal studies.

Acknowledgements
This article has been published as part of Microbial Cell Factories Volume 10 Supplement 1, 2011: Proceedings of the 10th Symposium on Lactic Acid Bacterium. The full contents of the supplement are available online at http://www.microbialcellfactories.com/supplements/10/S1.

Competing interests
The authors declare that they have no competing interests.

Published: 30 August 2011

References

1. Bermúdez-Humaran LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin 2009, 5(4):264-267.
2. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(4 Suppl):S45-S53.
3. Bermúdez-Humaran LG, Langella P. Perspectives for the development of human papillomavirus vaccines and immunotherapy. Expert Rev Vaccines 2010, 9(1):35-44.
4. Bahey-El-Din M, Gahan CG. Lactococcus lactis as a cell factory for production of therapeutic proteins. Curr Gene Ther 2010, 10(1):34-45.
5. Bahey-El-Din M, Gahan CG. Lactococcus lactis-based vaccines: Current status and future perspectives. Hum Vaccin 2011, 7(1).
6. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactococcal acid bacteria. Nat Rev Microbiol 2008, 6(5):349-362.
7. Bermúdez-Humaran LG, Corthier G, Langella P. Recent advances in the use of Lactococcus lactis as live recombinant vector for the development of new safe mucosal vaccines. Recent Res Devel Microbiol 2008, 4:147-160.
8. Morello E, Bermudez-Humaran LG, Llull D, Sole V, Miragoli N, Langella P, Poquet I. Lactococcus lactis, an efficient cell factory for recombinant protein production and secretion. J Mol Microbiol Biotechnol 2008, 14(1-3):45-58.
9. van Asseldonk M, Rutten G, Oteman M, Siezen RJ, de Vos WM. Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 1990, 95(1):135-160.
10. van Asseldonk M, de Vos WM, Simonis G. Functional analysis of the Lactococcus lactis usp45 secretion signal in the secretion of a homologous proteinase and a heterologous alpha-amylase. Mol Gen Genet 1993, 240(3):428-434.
11. Gasson MJ. Plasmid complements of Streptococcus lactis NCCD 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 1983, 154(1):1-9.
12. de Ruyter PG, Kuipers OP, Beerthuizen MM, van Alen-Boernger I, de Vos WM. Functional analysis of promoters in the nisin gene cluster of Lactococcus lactis. J Bacterial 1996, 178(12):3434-3439.
13. Kuipers OP, Beerthuizen MM, de Ruyter PG, Luesink EJ, de Vos WM. Autoregulation of nisin biosynthesis in Lactococcus lactis by signal transduction. J Biol Chem 1995, 270(45):27299-27304.
14. Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 2005, 68(8):705-717.
15. Le Loir Y, Guss A, Ehrlich SD, Langella P. Direct screening of recombinants in gram-positive bacteria using the secreted staphylococcal nuclease as a reporter. J Bacteriol 1996, 178(14):4333.
16. Le Loir Y, Guss A, Ehrlich SD, Langella P. A nine-residue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J Bacteriol 1998, 180(7):1895-1903.
17. Nouaille S, Morello E, Coritez-Peres N, Le Loir Y, Commissaire J, Gratadoux JJ, Poumerol E, Guss A, Langella P. Complementation of the Lactococcus lactis secretion machinery with Bacillus subtilis SecDF improves secretion of staphylococcal nuclease. Appl Environ Microbiol 2006, 72(2):2272-2279.
18. Poquet I, Saint V, Sezenc E, Simoes N, Bolotin A, Guss A. HtrA is the unique surface housekeeping protease in Lactococcus lactis and is required for natural protein processing. Mol Microbiol 2000, 35(5):1042-1051.
19. Frees D, Ingmer H. ClpP participates in the degradation of misfolded protein in Lactococcus lactis. Mol Microbiol 1999, 31(1):79-87.
20. Cortes-Perez NG, Poquet I, Oliveira M, Gratadoux JJ, Madisen SM, Miyoshi A, Corthier G, Azevedo V, Langella P, Bermudez-Humaran LG. Construction and characterization of a Lactococcus lactis strain deficient in intracellular ClpP and extracellular HtrA proteases. Microbiology 2006, 152(Pt 9):2611-2618.
21. Iwai M, Okahashi N, Takahashi I, Kanamoto T, Sugita-Konishi Y, Albira K, Koga T. Oral immunization with recombinant Streptococcus lactis carrying the Streptococcus mutans surface protein antigen gene. Infect Immun 1990, 58(9):2929-2934.
22. Wells JM, Wilson NW, Norton PM, Gasson MJ, Le Page RW. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol Microbiol 1995, 8(6):1155-1162.
23. Norton PM, Wells JM, Brown HW, Macpherson AM, Le Page RW. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 1997, 15(6-7):616-619.
24. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997, 15(7):653-657.
25. Bermudez-Humaran LG, Langella P, Miyoshi A, Guss A, Guerra RT, Montes-de-Oca-Luna R, Le Loir Y. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol 2002, 68(2):917-922.
26. Cortes-Perez NG, Bermudez-Humaran LG, Le Loir Y, Rodriguez-Padilla C, Guss A, Suauco-Cardenas O, Langella P, Montes-de-Oca-Luna R. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 2003, 229(1):37-42.
27. Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, Alcocer-Gonzalez JM, Tamez-Guerra RS, de Oca-Luna RW, Langella P. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004, 53(Pt 5):427-433.
28. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, Guimearas V, Rabot S, Alcocer-Gonzalez JM, Gratadoux JJ, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, et al. A novel mucosal vaccine based on live Lactococcus displaying E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005, 175(1):707-7102.
29. Exl BM, Frische R. Cow’s milk protein allergy and possible means for its prevention. Nutrition, 2001, 17(7-8):642-651.
30. Crittenden RG, Bennett LE. Cow’s milk allergy: a complex disorder. J Am Coll Nutr 2005, 24(6 Suppl):S582-S591.
31. Chatel JM, Langella P, Adel-Patient K, Commissaire J, Wal JM, Corthier G. Induction of mucosal immune response after intranasal or oral inoculation of mice with Lactococcus lactis producing bovine beta-lactoglobulin. Clin Diagn Lab Immunol 2001, 8(3):543-551.
32. Chatel JM, Nouaille S, Adel-Patient K, Le Loir Y, Boe H, Guss A, Wal JM, Langella P. Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice. Appl Environ Microbiol 2003, 69(11):6620-6627.
33. Adel-Patient K, Ah-Leung S, Creminon C, Nouaille S, Chatel JM, Langella P, Wal JM. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 2003, 33(4):329-346.
34. Cortes-Perez NG, Ah-Leung S, Bermudez-Humaran LG, Corthier G, Wal JM, Langella P, Adel-Patient K. Intranasal coadministration of live lactococci producing interleukin-12 and a major cow’s milk allergen inhibits allergic reaction in mice. Clin Vaccine Immunol 2007, 14(3):226-233.
35. Wu C, Yang G, Bermudez-Humaran LG, Pang Q, Zeng Y, Wang J, Gao X. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on
Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice. Int Immunopharmacol 2006, 6(4):610-615.

36. Cortes-Perez NG, Ah-Leung S, Bermudez-Humaran LG, Corthier G, Langella P, Wal JM, Adel-Patient K. Allergy therapy by intranasal administration with recombinant Lactobacillus lactis Producing bovine beta-lactoglobulin. Int Arch Allergy Immunol 2009, 150(1):25-31.

37. Zhang Y, Proença R, Maffé M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372(6505):425-432.

38. Montague CT, Farrow IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Dogby JE, Mohammed SH, Hurst JA, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1998, 392(6674):398-401.

39. Strobel A, Issad T, Camoin L, Ozata M, Strobel AD. A leptin mimick mutation associated with hypogonadism and morbid obesity. Nat Genet 1998, 18(3):213-215.

40. Clement K, Vasse C, Lahouli N, Cabrol S, Pelloux V, Casirato D, Gourmelon M, Dina C, Chambaz J, Lacorte JM, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998, 392(6674):398-401.

41. Stroebel AD, Issad T. The involvement of leptin in humans revealed by mutations in leptin and leptin receptor genes. Trends Pharmacol Sci 1999, 20(7):277-280.

42. Farrow IS, Jubb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O’Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999, 341(12):879-884.

43. Farrow IS, Matarese G, Lord GM, Georges J, Maffei M, Barone M, Leopold L, Friedman JM, Jubb SA, Ferrsa F, Fontana S, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002, 110(8):1109-1113.

44. Gibson WT, Farrow IS, Moreau M, DePaoli AM, Lawrence E, O’Rahilly S, Truswell SA. Congenital leptin deficiency due to homozygosity for the Delta136G mutation: report of another case and evaluation of response of four years of leptin therapy. J Clin Endocrinol Metab 2004, 89(10):4821-4826.

45. Licinio J, Cagliasan Y, Ozata M, Yildiz BO, van Riet C, Hamalainen P, Vartiainen K, Backelkka K, Laitinen K, et al. Phenotypic effects of leptin replacement on morbidity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004, 101(11):4531-4536.

46. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Kirwan F, Gourmelen M, Dina C, Chambaz J, Lacorte JM, et al. Beneficial effects of leptin on carbohydrate and lipid metabolism in nonobese subjects. J Clin Endocrinol Metab 2002, 87(12):5140-5144.

47. Caro JF, Kolaczynski JW, Nyce MR, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV. Beneficial effects of leptin on obesity, hyperglycaemia and dyslipidaemia in Pima Indians. J Clin Endocrinol Metab 1999, 84(10):3119-3124.

48. LeBlanc J, Bermudez-Humaran LG, Gratadoux JJ, Fourcade C, Hoebler C, Corthier G, Langella P. Anti-inflammatory effects of Lactobacillus casei strain NCC2823 producing superoxide dismutase and catalase in both in vitro and in vivo models of colitis. Inflamm Bowel Dis 2006, 12(1):1044-1052.

49. Carroll IM, Andrus JM, Bruno-Barcena JM, Klaenhammer TR, Hassan HM, Kamm MA. Once daily high dose superoxide dismutase in a mouse model of colitis. J Parenter Enteral Nutr 2005, 29(8):612-617.

50. Fouts TR, DeVico AL, Onyabe DY, Shata MT, Bagley KC, Lewis GK, Hone DM. Use of superoxide dismutase and catalase producing lactic acid bacteria for the treatment of Clostridium difficile-induced colitis. Microb Cell Fact 2011, 10:S7091-S7097.
72. Chatel JM, Pothelune L, Ah-Leung S, Cortier G, Bai JM, Langella P. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. Gene Ther 2008, 15(16):1184-1190.
73. Grillot-Courvalin C, Gossard S, Huetz F, Opici DM, Courvalin P. Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol 2009, 16(9):862-866.
74. Gaillard JL, Berche P, Freihel C, Guinou E, Cossart P. Entry of L. monocytogenes into cells is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive cocci. Cell 1991, 61(7):1127-1141.
75. Mengaud J, Ouyoung H, Gounon P, Milge RW, Cossart P. E-cadherin is the receptor for internalin, a surface protein required for entry of L. monocytogenes into epithelial cells. Cell 1996, 84(6):923-932.
76. Guimaraes VD, Gabriel JE, Lefevre F, Cabanes D, Gruss A, Cossart P, Azevedo V, Langella P. Intracellular-expressing Lactococcus lactis is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. Microbes Infect 2005, 7(15-16):836-844.
77. Innocenti S, Guimaeraes V, Miyoshi A, Azevedo V, Langella P, Chatel JM, Lefevre F. Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cell lines. Appl Environ Microbiol 2009, 75(14):4870-4878.
78. Lee P. Biocatalysis for bioclean: live bacteria vaccine vectors. Bioengineered Bugs 2010, 1(1):75-77.
79. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remon JP, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289(5483):1352-1355.
80. Steidler L, Neirynck S, Hueghaeber N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin-10. Nat Biotechnol 2003, 21(7):785-790.
81. Braat H, Rottiers P, Hommes DW, Hueghaeber N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 2006, 4(6):754-759.
82. Buccato S, Maione D, Rinaudo CD, Volpini G, Taddei AR, Rosini R, Telford JL, Grandi G, Margarit I. Expression of Helicobacter pylori cag12 gene in Lactococcus lactis mini-capsules. J Infect Dis 2005, 192(8):1441-1449.
83. Aires KA, Cianciarullo AM, Carneiro SM, Villa LM, Boccardo E, Perez-Martinez G, Perez-Arellano I, Oliveira ML, Ho PL. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol 2006, 72(17):745-752.
84. Lee TY, Kim IY, Lee JS, Kim CJ, Sung MH, Lee SH. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57BL/6 mice. Int J Cancer 2006, 119(7):1702-1709.
85. Cortes-Perez NG, Lefevre F, Cortier G, Adel-Patient K, Langella P, Bermudez-Humaran L. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 2007, 25:6581-6588.
86. Lee TY, Kim YH, Lee KS, Kim JK, Lee IH, Yang JM, Sung MH, Park JS, Poo H. Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice. Cancer Immunolog Therapeut 2010, 59(11):1727-1737.
87. Cho HJ, Shin HJ, Han IK, Jung WW, Kim YB, Sul D, Oh YK. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine 2007, 25(47):8049-8057.
88. Boros I, Kornai K, Csermely P, Gerevich A, Palatinus A, Buza A, Tarnoky Z, Poellner D, Ho PL. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol 2006, 72(17):745-752.
89. Lee HY, Yuan J, Wei X, Lamm DW. Immunoprotection against influenza HSV1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virolology 2010, 407(2):319-324.
90. Dieye Y, Hoekman AJ, Clier F, Juliard V, Boot HJ, Pard JC. Ability of Lactococcus lactis to export viral capsid antigens: a crucial step for development of live vaccines. Appl Environ Microbiol 2003, 69(12):7281-7288.
109. Perez CA, Eichwald C, Burrone O, Mendoza D: Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice. J Appl Microbiol 2005, 99(5):1158-1164.

110. Zhang Q, Zhong J, Huan L: Expression of hepatitis B virus surface antigen determinants in Lactococcus lactis for oral vaccination. Microbiol Res 2011, 166(2):111-120.

111. Steidler L, Robinson K, Chamberlain L, Schofield KM, Remaut E, Le Page RW, Wells JM: Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun 1998, 66(7):3183-3189.

112. Bermudez-Humaran LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, Oliveira SC, Saucedo-Cardenas O, Montes de Oca-Luna R, Le Loir Y: Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003, 71(4):1887-1896.

113. Cortes-Perez NG, da Costa Medina LF, Lefevre F, Langella P, Bermudez-Humaran LG: Production of biologically active CXC chemokines by Lactococcus lactis: evaluation of its potential as a novel mucosal vaccine adjuvant. Vaccine 2008, 26(46):5778-5783.

114. Bermudez-Humaran LG, Nouaille S, Zilberfarb V, Corthier G, Gruss A, Langella P, Issad T: Effects of intranasal administration of a leptin-secreting Lactococcus lactis recombinant on food intake, body weight, and immune response of mice. Appl Environ Microbiol 2007, 73(6):3300-3307.

115. Zhang ZH, Jiang PH, Li NJ, Shi M, Huang W: Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19). World J Gastroenterol 2005, 11(44):6975-6980.

116. Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, Leenhouts K: Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 2006, 24(18):3900-3908.

117. Chang YC, Lin CC, Hsu CH: Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria. Vaccine 2006, 24(33-34):5931-5936.

118. Lee P, Faubert GM: Oral immunization of BALB/c mice by intragastric delivery of Streptococcus gordonii-expressing Giardia cyst wall protein 2 decreases cyst shedding in challenged mice. FEMS Microbiol Lett 2006, 265(2):225-236.

119. Anuradha K, Foo HL, Mariana NS, Loh TC, Yusoff K, Hassan MD, Raha AR: Live recombinant Lactococcus lactis vaccine expressing aerolysin genes D1 and D4 for protection against Aeromonas hydrophila in tilapia (Oreochromis niloticus). J Appl Microbiol 2010, 109(5):1632-1642.

120. Watterlot L, Rochat T, Sokol H, Cherbuy C, Bouloufa I, Lefevre F, Gratadoux JJ, Honvo-Hueto E, Chilmonczyk S, Bluegon S, et al: Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol 2010, 144(1):35-41.

doi:10.1186/1475-2859-10-51-54

Cite this article as: Bermúdez-Humarán et al: Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microbial Cell Factories 2011, 10(Suppl 1):S4.